Research Papers:

βTrCP controls the lysosome-mediated degradation of CDK1, whose accumulation correlates with tumor malignancy

Joaquín Herrero-Ruiz, Mar Mora-Santos, Servando Giráldez, Carmen Sáez, Miguel Á. Japón, Maria Tortolero and Francisco Romero _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:7563-7574. https://doi.org/10.18632/oncotarget.2274

Metrics: PDF 2542 views  |   HTML 3282 views  |   ?  


Joaquín Herrero-Ruiz1, Mar Mora-Santos1, Servando Giráldez1, Carmen Sáez2, Miguel Á. Japón2, Maria Tortolero1 and Francisco Romero1

1 Departamento de Microbiología, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain

2 Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla and Departamento de Anatomía Patológica, Hospital Universitario Virgen del Rocío, Sevilla, Spain


Francisco Romero, email:

Keywords: apoptosis/ autophagy/ βTrCP/ cancer/ CDK1

Received: May 22, 2014 Accepted: July 26, 2014 Published: July 27, 2014


In mammals, cell cycle progression is controlled by cyclin-dependent kinases, among which CDK1 plays important roles in the regulation of the G2/M transition, G1 progression and G1/S transition. CDK1 is highly regulated by its association to cyclins, phosphorylation and dephosphorylation, changes in subcellular localization, and by direct binding of CDK inhibitor proteins. CDK1 steady-state protein levels are held constant throughout the cell cycle by a coordinated regulation of protein synthesis and degradation. We show that CDK1 is ubiquitinated by the E3 ubiquitin ligase SCFβTrCP and degraded by the lysosome. Furthermore, we found that DNA damage not only triggers the stabilization of inhibitory phosphorylation sites on CDK1 and repression of CDK1 gene expression, but also regulates βTrCP-induced CDK1 degradation in a cell type-dependent manner. Specifically, treatment with the chemotherapeutic agent doxorubicin in certain cell lines provokes CDK1 degradation and induces apoptosis, whereas in others it inhibits destruction of the protein. These observations raise the possibility that different tumor types, depending on their pathogenic spectrum mutations, may display different sensitivity to βTrCP-induced CDK1 degradation after DNA damage. Finally, we found that CDK1 accumulation in patients’ tumors shows a negative correlation with βTrCP and a positive correlation with the degree of tumor malignancy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2274